Hypoxia-inducible enhancer/α-fetoprotein promoter-driven RNA interference targeting STK15 suppresses proliferation and induces apoptosis in human hepatocellular carcinoma cells

Cancer Science

Volumn 99, Issue 11, 2008, Pages 2209-2217

  Gao, Ping ^a   Wang, Rui ^a   Shen, Jian Jun ^a   Lin, Fang ^a   Wang, Xi ^a   Dong, Ke ^a   Zhang, Hui Zhong ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN; AURORA A KINASE; ENHANCED GREEN FLUORESCENT PROTEIN; FIREFLY LUCIFERASE; SHORT HAIRPIN RNA;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CARCINOGENICITY; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFICACY; DRUG MECHANISM; DRUG SPECIFICITY; DRUG TARGETING; GENE EXPRESSION; GENE VECTOR; HUMAN; HUMAN CELL; IN VITRO STUDY; LIVER CELL CARCINOMA; NONVIRAL GENE DELIVERY SYSTEM; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; RNA INTERFERENCE;

ALPHA-FETOPROTEINS; ANIMALS; ANOXIA; APOPTOSIS; BASE SEQUENCE; CARCINOMA, HEPATOCELLULAR; CELL PROLIFERATION; DOWN-REGULATION; ENHANCER ELEMENTS, GENETIC; FEMALE; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1; LIVER NEOPLASMS; MICE; MICE, NUDE; MOLECULAR SEQUENCE DATA; PROMOTER REGIONS, GENETIC; PROTEIN-SERINE-THREONINE KINASES; RNA INTERFERENCE; TUMOR CELLS, CULTURED;

EID: 55449132571     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2008.00941.x     Document Type: Article

References (49)

1. Farazi PA, DePinho RA. Hepatocellular carcinoma pathogenesis: From genes to environment, Nat Rev Cancer 2006; 6: 674-7.
2. El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 1999; 340: 745-50.
3. Parkin DM, Bray F, Ferlay J et al. Global cancer statistics 2002. CA Cancer J Clin 2005; 55: 74-108.
4. Davila JA, Morgan RO, Shaib Y et al. Hepatitis C infection and the increasing incidence of hepatocellular carcinoma: A population-based study. Gastroenterology 2004; 127: 1372-80.
5. Zhou H, Kuang J, Zhong L et al. Tumour amplified kinase STK15/BTAK induces centrosome amplification, aneuploidy and transformation. Nat Genet 1998; 20: 189-93.
6. Carmena M, Earnshaw WC. The cellular geography of aurora kinases. Nat Rev Mol Cell Biol 2003; 4: 842-54.
7. Royce ME, Xia W, Sahin AA et al. STK15/Aurora-A expression in primary breast tumors is correlated with nuclear grade but not with prognosis. Cancer 2004; 100: 12-9.
8. Reiter R, Gais P, Jütting U et al. Aurora kinase A messenger RNA overexpression is correlated with tumor progression and shortened survival in head and neck squamous cell carcinoma. Clin Cancer Res 2006; 12: 5136-41.
9. Li D, Zhu J, Firozi PF et al. Overexpression of oncogenic STK15/BTAK/ Aurora A kinase in human pancreatic cancer. Clin Cancer Res 2003; 9: 991-7.
10. Yang SB, Zhou XB, Zhu HX et al. Amplification and overexpression of Aurora-A in esophageal squamous cell carcinoma. Oncol Rep 2007; 17: 1083-8.
11. Jeng YM, Peng SY, Lin CY et al. Overexpression and amplification of Aurora-A in hepatocellular carcinoma. Clin Cancer Res 2004; 10: 2065-71.
12. Bolanos-Garcia VM. Aurora kinases. Int J Biochem Cell Biol 2005; 37: 1572-7.
13. Fumoto S, Nishi J, Nakamura J et al. Gene therapy for gastric diseases. Curr Gene Ther 2008; 8: 187-200.
14. Oger J. Immunosuppression: Promises and failures. J Neurol Sci 2007; 259: 74-8.
15. Shim JS, Park HM, Lee J et al. Global and focused transcriptional profiling of small molecule aminopeptidase N inhibitor reveals its mechanism of angiogenesis inhibition. Biochem Biophys Res Commun 2008; 371: 99-103.
16. Gunduz M, Gunduz E, Rivera RS et al. The inhibitor of growth (ING) gene family: Potential role in cancer therapy. Curr Cancer Drug Targets 2008; 8: 275-84.
17. Sui G, Soohoo C, Affar el B et al. A DNA vector-based RNAi technology to suppress gene expression in mammalian cells. Proc Natl Acad Sci USA 2002; 99: 5515-20.
18. Brummelkamp TR, Bernards R, Agami R. A system for stable expression of short interfering RNAs in mammalian cells. Science 2000; 296: 550-3.
19. Kwak YD, Koike H, Sugaya K. RNA interference with small hairpin RNAs transcribed from a human U6 promoter-driven DNA vector. Pharmacol Sci 2003; 93: 214-7.
20. Myslinski E, Amé JC, Krol A et al. An unusually compact external promoter for RNA polymerase III transcription of the human H1RNA gene. Nucleic Acids Res 2001; 29: 2502-9.
21. Scherer LJ, Frank R, Rossi JJ. Optimization and characterization of tRNA-shRNA expression constructs. Nucl Acids Res 2007; 35: 2620-8.
22. Huang SL, Wu Y, Yu H et al. Inhibition of Bcl-2 expression by a novel tumor-specific RNA interference system increases chemosensitivity to 5-fluorouracil in Hela cells. Acta Pharmacologica Sinica 2006; 27: 242-8.
23. Chen JS, Liu JC, Shen L et al. Cancer-specific activation of the survivin promoter and its potential use in gene therapy. Cancer Gene Ther 2004; 11: 740-7.
24. Kang YA, Shin HC, Yoo JY et al. Novel cancer antiangiotherapy using the VEGF promoter-targeted artificial zinc-finger protein and oncolytic adenovirus. Mol Ther 2008; 16: 1033-40.
25. Willhauck MJ, Sharif Samani BR, Klutz K et al. Alpha-fetoprotein promoter-targeted sodium iodide symporter gene therapy of hepatocellular carcinoma. Gene Ther 2008; 15: 214-23.
26. Liu T, Zhang G, Chen YH et al. Tissue specific expression of suicide genes delivered by nanoparticles inhibits gastric carcinoma growth. Cancer Biol Ther 2006; 5: 1683-90.
27. Orito E, Mizokami M. Differences of HBV genotypes and hepatocellular carcinoma in Asian countries. Hepatol Res 2007; 37: S33-5.
28. Hainaut P, Boyle P. Curbing the liver cancer epidemic in Africa. Lancet 2008; 371: 367-8.
29. Llovet JM, Bruix J. Novel advancements in the management of hepatocellular carcinoma in 2008. J Hepatol 2008; 48: S20-37.
30. El-Serag HB, Marrero JA, Rudolph L et al. Diagnosis and treatment of hepatocellular carcinoma. Gastroenterology 2008; 134: 1752-63.
31. Wilda M, Fuchs U, Borkhardt A. Killing of leukemic cells with a BCR/ABL fusion gene by RNA interference (RNAi). Oncogene 2002; 21: 5716-24.
32. Jacque JM, Triques K, Stevenson M. Modulation of HIV-1 replication by RNA interference. Nature 2002; 418: 435-8.
33. Shlomai A, Shaul Y. Inhibition of hepatitis B virus expression replication by RNA interference. Hepatology 2003; 37: 764-70.
34. Walchli S, Sioud M. Vector-based delivery of siRNAs: In vitro and in vivo challenges. Front Biosci 2008; 13: 3488-93.
35. Ali M, Sahib MK. Developmental changes in the expression of alpha-fetoprotein and albumin genes in rat liver: Correlation of rates of synthesis of the two proteins in the hepatocytes, their hepatic contents and serum levels during development. Indian J Biochem Biophys 1983; 20: 218-21.
36. Lu SY, Sui YF, Li ZS et al. Construction of a regulable gene therapy vector targeting for hepatocellular carcinoma. World J Gastroenterol 2003; 9: 688-91.
37. Pin RH, Reinblatt M, Fong Y. Utilizing alpha-fetoprotein expression to enhance oncolytic viral therapy in hepatocellular carcinoma. Ann Surg 2004; 240: 659-65; discussion 665-6.
38. Wang GL, Jiang BH, Rue EA et al. Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci USA 1995; 92: 5510-14.
39. Ido A, Uto H, Moriuchi A et al. Gene therapy targeting for hepatocellular carcinoma: Selective and enhanced suicide gene expression regulated by a hypoxia-inducible enhancer linked to a human alpha-fetoprotein promoter. Cancer Res 2001; 61: 3016-21.
40. Mazure NM, Chauvet C, Bois-Joyeux B et al. Repression of alpha-fetoprotein gene expression under hypoxic conditions in human hepatoma cells: Characterization of a negative hypoxia response element that mediates opposite effects of hypoxia inducible factor-1 and c-Myc. Cancer Res 2002; 62: 1158-65.
41. Adams RR, Carmena M, Earnshaw WC. Chromosomal passengers and the (aurora) ABCs of mitosis. Trends Cell Biol 2001; 11: 49-54.
42. Tong T, Zhong Y, Kong J et al. Overexpression of Aurora-A contributes to malignant development of human esophageal squamous cell carcinoma. Clin Cancer Res 2004; 10: 7304-10.
43. Hata T, Furukawa T, Sunamura M et al. RNA interference targeting aurora kinase a suppresses tumor growth and enhances the taxane chemosensitivity in human pancreatic cancer cells. Cancer Res 2005; 65: 2899-905.
44. Tanaka E, Hashimoto Y, Ito T et al. The suppression of aurora-A/STK15/ BTAK expression enhances chemosensitivity to docetaxel in human esophageal squamous cell carcinoma. Clin Cancer Res 2007; 13: 1331-40.
45. Lan B, Liu BY, Chen XH et al. Inhibition of serine/threonine kinase 15 gene expression induces apoptosis of gastric cancer cells. Zhonghua Wei Chang Wai Ke Za Zhi 2006; 9: 417-20.
46. Keen N, Taylor S. Aurora-kinase inhibitors as anticancer agents. Nat Rev Cancer 2004; 4: 927-36.
47. Meng R, Wu G, Cheng J et al. The effect of antisense oligodeoxynucleotides targeting Aurora A kinase on cell proliferation and chemosensitivity to paclitaxel in human lung cancer cell line A549. Chinese-German J Clin Oncol 2007; 6: 258-63.
48. Du J, Hannon GJ. Suppression of p160ROCK bypasses cell cycle arrest after Aurora-A/STK15 depletion. Proc Natl Acad Sci USA 2004; 101: 8975-80.
49. Tao Y, Zhang P, Frascogna V et al. Enhancement of radiation response by inhibition of Aurora-A kinase using siRNA or a selective Aurora kinase inhibitor PHA680632 in p53-deficient cancer cells. Br J Cancer 2007; 97: 1664-72.